Navigation Links
Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team
Date:6/28/2011

MINNEAPOLIS, June 28, 2011 /PRNewswire/ -- Lutonix today announced receiving approval from the US Food and Drug Administration to begin enrollment in its LEVANT 2 IDE clinical trial for the treatment of peripheral arterial disease (PAD), along with receipt of CE Mark for its drug-coated balloon and ISO certification.  Lutonix is the first company to receive approval from the FDA to initiate a drug-coated balloon trial.  

The company also announced two new additions to its leadership team.  Shawn McCormick was named Chief Operating Officer and will oversee manufacturing, R&D, finance and administration for the company.  Leslie Trigg was named Executive Vice President, Marketing and Commercial Strategy and will oversee all commercialization aspects of the business.

LEVANT 2 Trial Set to Begin

LEVANT 2 is a global, multicenter, randomized study evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for treating diseased leg arteries above the knee.  The trial is designed to support an application to the US FDA for approval of the Moxy balloon.  Co-principal investigators for this international study are Dr. Ken Rosenfield (Massachusetts General Hospital, Boston MA) and Dr. Dierk Scheinert (University of Leipzig, Leipzig Germany).

The LEVANT 2 trial was preceded by LEVANT 1, a multi-center, prospective randomized trial of 101 patients with PAD.  In this study, the Moxy balloon was compared to standard angioplasty.  Data presented during the 2010 Transcatheter Cardiovascular Therapeutics meeting showed that the Moxy balloon had the ability to safely and substantially inhibit restenosis.

"Finding a durable treatment for PAD has proven to be one our most difficult clinical challenges," said Dr. Rosenfield.  "PAD patients are in great need of better treatment options.  This trial is an important step forward
'/>"/>

SOURCE Lutonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lutonix Inc. Announces $20 Million Series B Financing
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... LEIDEN, Netherlands, March 8, 2011 Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) today announced that ... Subsequent Offering Period), Johnson & Johnson has acquired 98.89% ... treasury shares held by Crucell) and 98.93% of the issued ...
... 2011 Sequenom, Inc. (Nasdaq: SQNM ) today ... year ended December 31, 2010. (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ... Total revenue for the fourth quarter of 2010 grew 28% ... quarter of 2009. The increase in revenue compared to the ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 2Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 3Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 4Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 5Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 6Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 8Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 9
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... ... Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. Collazo, ... Collazo, a 15 year veteran of helping drug, biologic and device firms reduce ...
(Date:7/30/2015)... ... 30, 2015 , ... World Patent Marketing, a vertically integrated ... that can help people during emergencies. , "The worldwide mobile health market revenue ... of World Patent Marketing. "Currently, there are about 97,000 mobile health apps available ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by ... , The decision will also allow him to spend more time in the office ... admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3
... women need screening as much as younger ones, , , ... should continue for women older than 50 -- even ... they have a similar level of risk as younger ... there,s little benefit in repeating smear tests in women ...
... As federal policymakers pursue healthcare reform this year, the ... prevention will be critically evaluated. As part of ... North America,s top medical schools will host scientists from ... the area of integrative medicine. The Consortium ...
... genetic study conducted through Mayo Clinic has identified ... European ancestry, according to a recent issue of ... , Research findings indicate that alcohol dependence ... variations associated with this illness remain unknown. Animal ...
... Holistic Addiction Treatment has added the use of Mild Hyperbarics to drug ... Scotland and Russia, mild hyperbarics is not generally associated with drug and ... alcohol treatment and recovery services that meet the needs of the person ... ...
... finds vets at higher risk of aggressive recurrence only ... News) -- U.S. male military veterans exposed to the ... recurrence of prostate cancer, a new study finds. , ... cancerous prostates. Of those, the 206 men who,d been ...
... Health Ministry Official shows programs funded by the Global Fund and President,s ... , ... Washington, DC (PRWEB) April 23, 2009 -- At a Congressional ... discussed the current state of malaria in Rwanda and how ...
Cached Medicine News:Health News:Don't Lower Age for Cervical Cancer Test, Study Urges 2Health News:Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers 2Health News:Mayo clinic study finds gene bringing together animal and human research in alcoholism 2Health News:G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab 2Health News:G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab 3Health News:Agent Orange Exposure Tied to Prostate Cancer Return 2Health News:A View from Rwanda: Congressional Briefing Highlights Impact of U.S. funded Anti-Malaria Programs 2Health News:A View from Rwanda: Congressional Briefing Highlights Impact of U.S. funded Anti-Malaria Programs 3
An Antiseptic - Antibacterial Cleanser that helps reduce bacteria that can potentially cause disease.Does not produce the systemic adverse effects associated with iodine or iodine by-products and is ...
... for professional degerming, pre-op and post-op ... combining quaternary and substituted phenolic active ... emollients and surfactants. Unprecedented efficacy on ... in 30 seconds. Techni-Care represents a ...
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... pouches are designed for individual application and ... used in nursing homes, home healthcare settings, ... other hospital departments. This unit dose pouch ... antiseptic, germicidal and cleansing agent. Hydrogen Peroxide's ...
Medicine Products: